These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 31585174)

  • 1. Reporting of randomized factorial trials was frequently inadequate.
    Kahan BC; Tsui M; Jairath V; Scott AM; Altman DG; Beller E; Elbourne D
    J Clin Epidemiol; 2020 Jan; 117():52-59. PubMed ID: 31585174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis and reporting of factorial trials: a systematic review.
    McAlister FA; Straus SE; Sackett DL; Altman DG
    JAMA; 2003 May; 289(19):2545-53. PubMed ID: 12759326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reporting of factorial trials of complex interventions in community settings: a systematic review.
    Montgomery AA; Astin MP; Peters TJ
    Trials; 2011 Jul; 12():179. PubMed ID: 21771302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
    Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
    Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The 2 × 2 cluster randomized controlled factorial trial design is mainly used for efficiency and to explore intervention interactions: a systematic review.
    Mdege ND; Brabyn S; Hewitt C; Richardson R; Torgerson DJ
    J Clin Epidemiol; 2014 Oct; 67(10):1083-92. PubMed ID: 25063555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimands for factorial trials.
    Kahan BC; Morris TP; Goulão B; Carpenter J
    Stat Med; 2022 Sep; 41(22):4299-4310. PubMed ID: 35751568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two-by-Two Factorial Cancer Treatment Trials: Is Sufficient Attention Being Paid to Possible Interactions?
    Freidlin B; Korn EL
    J Natl Cancer Inst; 2017 Sep; 109(9):. PubMed ID: 28954288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An examination of effect estimation in factorial and standardly-tailored designs.
    Allore HG; Murphy TE
    Clin Trials; 2008; 5(2):121-30. PubMed ID: 18375650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Designs for efficient clinical trials.
    Simon R
    Oncology (Williston Park); 1989 Jul; 3(7):43-9; discussion 51-3. PubMed ID: 2701811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factorial design considerations.
    Green S; Liu PY; O'Sullivan J
    J Clin Oncol; 2002 Aug; 20(16):3424-30. PubMed ID: 12177102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomization procedures for multicomponent behavioral intervention factorial trials in the multiphase optimization strategy framework: challenges and recommendations.
    Gallis JA; Bennett GG; Steinberg DM; Askew S; Turner EL
    Transl Behav Med; 2019 Nov; 9(6):1047-1056. PubMed ID: 30590759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Partial factorial trials: comparing methods for statistical analysis and economic evaluation.
    Dakin HA; Gray AM; MacLennan GS; Morris RW; Murray DW
    Trials; 2018 Aug; 19(1):442. PubMed ID: 30115104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic Evaluation of Patient-Reported Outcome Protocol Content and Reporting in Cancer Trials.
    Kyte D; Retzer A; Ahmed K; Keeley T; Armes J; Brown JM; Calman L; Gavin A; Glaser AW; Greenfield DM; Lanceley A; Taylor RM; Velikova G; Brundage M; Efficace F; Mercieca-Bebber R; King MT; Turner G; Calvert M
    J Natl Cancer Inst; 2019 Nov; 111(11):1170-1178. PubMed ID: 30959516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factorial designs in clinical trials: the effects of non-compliance and subadditivity.
    Brittain E; Wittes J
    Stat Med; 1989 Feb; 8(2):161-71. PubMed ID: 2704898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency and reasons for outcome reporting bias in clinical trials: interviews with trialists.
    Smyth RM; Kirkham JJ; Jacoby A; Altman DG; Gamble C; Williamson PR
    BMJ; 2011 Jan; 342():c7153. PubMed ID: 21212122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distributive randomization: a pragmatic fractional factorial design to screen or evaluate multiple simultaneous interventions in a clinical trial.
    Haviari S; Mentré F
    BMC Med Res Methodol; 2024 Mar; 24(1):64. PubMed ID: 38468221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trial designs for evaluating combination HIV prevention approaches.
    Chen YQ; Peng L; Wang Y; Appelmans E; Dasgupta S; Fleming TR
    HIV Res Clin Pract; 2020; 21(2-3):72-82. PubMed ID: 32698705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of intervention reporting in published emergency medicine clinical trials.
    Fladie IA; Rorah D; Pollard J; Jellison S; Thabane L; Murray K; Gardner G; Vassar M
    Am J Emerg Med; 2020 Jun; 38(6):1171-1177. PubMed ID: 32340822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.